Immunosuppressive treatments in multiple sclerosis

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Multiple sclerosis (MS) is a heterogeneous autoimmune disorder of the central nervous system that is enigmatic, relapsing, and in some instances progressive. Prior to the discovery, study, and utilization of the US Food and Drug Administration (FDA)-approved disease-modifying therapies (i.e., interferon class of medications or glatiramer acetate), and even before the advent of magnetic resonance imaging technology as a diagnostic or clinical surveillance tool, immunosuppressive treatments served as essential medical therapy for patients with MS. Currently, immunosuppressive agents are being utilized as monotherapy or in combination with parenterally administered immunomodulators for those who are suboptimal responders, are intolerant or experience adverse reactions to disease-modifying treatments, or for patients who exhibit an aggressive disease course. This chapter focuses on the most widely used immunosuppressive treatments in MS: cyclophosphamide, methotrexate, azathioprine, mycophenolate mofetil, and the only FDA-approved chemotherapeutic agent for the treatment of MS, mitoxandrone. Seminal data regarding its use in MS, the known mechanism(s) of action, and contemporary studies focusing on efficacy and safety data will be reviewed. The role of these chemotherapeutic agents in the management of MS and implications for therapeutic intervention are also discussed.

Original languageEnglish (US)
Pages (from-to)503-511
Number of pages9
JournalHandbook of Clinical Neurology
Volume122
DOIs
StatePublished - 2014

Fingerprint

Immunosuppressive Agents
Multiple Sclerosis
United States Food and Drug Administration
Therapeutics
Autoimmune Diseases of the Nervous System
Mycophenolic Acid
Azathioprine
Immunologic Factors
Methotrexate
Cyclophosphamide
Interferons
Magnetic Resonance Imaging
Technology
Safety

Keywords

  • Aggressive disease
  • Azathioprine
  • Complications of therapy
  • Cyclophosphamide
  • Methotrexate
  • Mitoxantrone
  • Mycophenolate mofetil
  • Progressive disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Immunosuppressive treatments in multiple sclerosis. / Okuda, Darin T.

In: Handbook of Clinical Neurology, Vol. 122, 2014, p. 503-511.

Research output: Contribution to journalArticle

@article{7c5bc41815714f699c6426d2b79f1749,
title = "Immunosuppressive treatments in multiple sclerosis",
abstract = "Multiple sclerosis (MS) is a heterogeneous autoimmune disorder of the central nervous system that is enigmatic, relapsing, and in some instances progressive. Prior to the discovery, study, and utilization of the US Food and Drug Administration (FDA)-approved disease-modifying therapies (i.e., interferon class of medications or glatiramer acetate), and even before the advent of magnetic resonance imaging technology as a diagnostic or clinical surveillance tool, immunosuppressive treatments served as essential medical therapy for patients with MS. Currently, immunosuppressive agents are being utilized as monotherapy or in combination with parenterally administered immunomodulators for those who are suboptimal responders, are intolerant or experience adverse reactions to disease-modifying treatments, or for patients who exhibit an aggressive disease course. This chapter focuses on the most widely used immunosuppressive treatments in MS: cyclophosphamide, methotrexate, azathioprine, mycophenolate mofetil, and the only FDA-approved chemotherapeutic agent for the treatment of MS, mitoxandrone. Seminal data regarding its use in MS, the known mechanism(s) of action, and contemporary studies focusing on efficacy and safety data will be reviewed. The role of these chemotherapeutic agents in the management of MS and implications for therapeutic intervention are also discussed.",
keywords = "Aggressive disease, Azathioprine, Complications of therapy, Cyclophosphamide, Methotrexate, Mitoxantrone, Mycophenolate mofetil, Progressive disease",
author = "Okuda, {Darin T.}",
year = "2014",
doi = "10.1016/B978-0-444-52001-2.00022-4",
language = "English (US)",
volume = "122",
pages = "503--511",
journal = "Handbook of clinical neurology / edited by P.J. Vinken and G.W. Bruyn",
issn = "0072-9752",
publisher = "Elsevier",

}

TY - JOUR

T1 - Immunosuppressive treatments in multiple sclerosis

AU - Okuda, Darin T.

PY - 2014

Y1 - 2014

N2 - Multiple sclerosis (MS) is a heterogeneous autoimmune disorder of the central nervous system that is enigmatic, relapsing, and in some instances progressive. Prior to the discovery, study, and utilization of the US Food and Drug Administration (FDA)-approved disease-modifying therapies (i.e., interferon class of medications or glatiramer acetate), and even before the advent of magnetic resonance imaging technology as a diagnostic or clinical surveillance tool, immunosuppressive treatments served as essential medical therapy for patients with MS. Currently, immunosuppressive agents are being utilized as monotherapy or in combination with parenterally administered immunomodulators for those who are suboptimal responders, are intolerant or experience adverse reactions to disease-modifying treatments, or for patients who exhibit an aggressive disease course. This chapter focuses on the most widely used immunosuppressive treatments in MS: cyclophosphamide, methotrexate, azathioprine, mycophenolate mofetil, and the only FDA-approved chemotherapeutic agent for the treatment of MS, mitoxandrone. Seminal data regarding its use in MS, the known mechanism(s) of action, and contemporary studies focusing on efficacy and safety data will be reviewed. The role of these chemotherapeutic agents in the management of MS and implications for therapeutic intervention are also discussed.

AB - Multiple sclerosis (MS) is a heterogeneous autoimmune disorder of the central nervous system that is enigmatic, relapsing, and in some instances progressive. Prior to the discovery, study, and utilization of the US Food and Drug Administration (FDA)-approved disease-modifying therapies (i.e., interferon class of medications or glatiramer acetate), and even before the advent of magnetic resonance imaging technology as a diagnostic or clinical surveillance tool, immunosuppressive treatments served as essential medical therapy for patients with MS. Currently, immunosuppressive agents are being utilized as monotherapy or in combination with parenterally administered immunomodulators for those who are suboptimal responders, are intolerant or experience adverse reactions to disease-modifying treatments, or for patients who exhibit an aggressive disease course. This chapter focuses on the most widely used immunosuppressive treatments in MS: cyclophosphamide, methotrexate, azathioprine, mycophenolate mofetil, and the only FDA-approved chemotherapeutic agent for the treatment of MS, mitoxandrone. Seminal data regarding its use in MS, the known mechanism(s) of action, and contemporary studies focusing on efficacy and safety data will be reviewed. The role of these chemotherapeutic agents in the management of MS and implications for therapeutic intervention are also discussed.

KW - Aggressive disease

KW - Azathioprine

KW - Complications of therapy

KW - Cyclophosphamide

KW - Methotrexate

KW - Mitoxantrone

KW - Mycophenolate mofetil

KW - Progressive disease

UR - http://www.scopus.com/inward/record.url?scp=84893483687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893483687&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-52001-2.00022-4

DO - 10.1016/B978-0-444-52001-2.00022-4

M3 - Article

C2 - 24507533

AN - SCOPUS:84893483687

VL - 122

SP - 503

EP - 511

JO - Handbook of clinical neurology / edited by P.J. Vinken and G.W. Bruyn

JF - Handbook of clinical neurology / edited by P.J. Vinken and G.W. Bruyn

SN - 0072-9752

ER -